

When Fluids are Not Enough: Inopressor Therapy



Problems in Neonatology

- Neonatal problem: hypoperfusion
 - Severe sepsis
 - Hallmark of septic shock
 - Secondary to neonatal encephalopathy
 - Vasoplegia Syndrome??
- First line therapy
 - Fluid loading – 20 ml/kg boluses
- Inopressor therapy
 - Inotropic therapy
 - Pressor therapy

Treating Hypoperfusion

- GOAL: return of perfusion
 - Not to achieve a given set of blood pressure values
- Measure of perfusion
 - Flow is proportional to left ventricular output
 - Flow is inversely proportional to vascular resistance
 - BP is a measure of these
- But...
 - High blood pressure \neq flow
 - Low blood pressure \neq no flow

BP and Capillary Perfusion


Clinical Experience

- BP does not correlate with microcirculatory flow
- Increasing BP with noradrenaline
 - Unpredictable effects on capillary perfusion
- Normalizing BP with pure vasoconstrictor
 - Phenylephrine
 - Decrease microcirculatory perfusion
- Impaired cardiac function
 - Vasopressor increases afterload
 - Reduce cardiac output with increase BP
 - No benefit global perfusion

Perfusion Physiology

- Normal foal
 - BP \neq perfusion (tissue blood flow)
 - Microcirculation controlled by metabolic demand
 - ADP, K, H⁺ or NO (shear stress), O₂ levels
- When decrease BP
 - Sympathetic control
 - Overrides tissue-driven blood flow regulation
 - Baroreceptors response
 - Peripheral vasoconstriction to preserve
 - Preserve heart and brain perfusion
 - At expense of global tissue hypoperfusion
- Shock

Hydrostatic Pressure



Permissive Hypotension Tissue Perfusion-based Approach



Resuscitation Endpoints

Dünser et al

- Step one

Target BP to preserve heart and brain perfusion

Each individual will have a different target

- Step two

Target tissue perfusion-based endpoints

Currently no reliable microcirculatory perfusion markers

Indirect/Downstream markers of tissue perfusion

- Arterial lactate, peripheral perfusion, urine output, central venous oxygen saturation
- Macrohemodynamic variables minor importance (BP,CO)

Resuscitation Endpoints

Dünser et al

- Step three

Target markers of single-organ perfusion

Kidneys

- Poorest capability to adjust to reductions in blood flow

- Increasing noradrenaline doses

May augment kidney perfusion and urine output

Poor correlation of BP and renal perfusion

- Need to insure as move through steps

That previous target is not negated

- May need to decrease adrenergic support

To achieve the target

- Therapy must not be guided by BP alone



Inopressor Therapy

Adrenergic Agonists

- Pharmacokinetics varies with individual
 - Plasma half-life
 - Receptor density
 - Receptor affinity
 - Receptor reactivity
 - Plasma pH
- Dose tailored to individual CRI
 - Short half-life
 - Effect of new dose evident within 10 to 15 minutes
 - Effective Dose may change with time
- Goal: Withdraw therapy as soon as possible

Inopressor Therapy

"Rule of 6"

- Dopamine, dobutamine - $1 \mu\text{g}/\text{kg}/\text{min}$
 $6 \times \text{wt (kg)} = \# \text{ mg added to 100 ml}$
1 ml/hr infusion = $1 \mu\text{g}/\text{kg}/\text{min}$. drug delivery
- Adrenaline , noradrenaline – $0.1 \mu\text{g}/\text{kg}/\text{min}$
 $0.6 \times \text{wt (kg)} = \# \text{ mg added to 100 ml}$
1 ml/hour infusion = $0.1 \mu\text{g}/\text{kg}/\text{min}$. drug delivery
- Take out amount added

Inopressor Therapy Adrenergic Agonists

- Ensure cardiac output
- Pressors without inotropic support
 - Cardiac output may fall
 - Perfusion may decrease
 - Despite rise in blood pressure numbers
- Inotropic support almost always indicated
- Mixed inotropic and pressor support
 - Inopressor support
 - Selecting an inotrope
 - Dobutamine
 - Medium dose dopamine
 - Low dose noradrenaline
 - Adrenaline
 - If inotropic effect does not increase perfusion adequately
 - Add a pressor

Inopressor Therapy

Adverse Effects

- Pharmacologic doses of adrenergic agonists
 - Increase in perfusion
 - Increase in maldistribution of that perfusion
 - Balanced between
 - Improved perfusion
 - Exaggerated maldistribution
- Aggressive support
 - “Industrial strength” agents
 - Goal: returning perfusion to minimally acceptable levels
 - Not to try to achieve normal perfusion
 - Not to try to achieve supernormal perfusion
 - Result in disastrous effects

Inopressor Therapy Dobutamine

- Good inotrope
 - Primarily β_1 activity
 - at low to moderate doses
- In man
 - Mild vasodilation
 - Some α_2 activity
 - Well balanced α_1 and α_2 stimulus
- In horses
 - At high doses
 - Significant vasoconstriction
 - α_1 activity appears
 - Inopressor at high doses

Inopressor Therapy

Dobutamine

- When support needed but not shocky
 - Begin 3-5 $\mu\text{g}/\text{kg}/\text{min}$
 - Titrate to effective dose
- With severe sepsis, septic shock
 - Begin 5-10 $\mu\text{g}/\text{kg}/\text{min}$
 - Titrate to effective dose
- Dose range is 2-20 $\mu\text{g}/\text{kg}/\text{min}$
 - Occasional cases - 50 $\mu\text{g}/\text{kg}/\text{min}$
- Adverse reactions
 - Tachycardia
 - Occasional arrhythmias

Inopressor Therapy Dopamine

- Low doses - dopaminergic activity
- Moderate doses - β 1 & β 2 activity
- High doses - α 1 activity
 - noradrenaline release from nerve terminals
 - Major mode of action at high doses??
 - Limitation with depletion in critical patients
- Inopressor
- Complex GI actions
 - Dysmotility

Inopressor Therapy Dopamine

- When support needed but not shocky
 - Begin 3-5 $\mu\text{g}/\text{kg}/\text{min}$
 - Titrate to effective dose
- With severe sepsis, septic shock
 - Begin 5-10 $\mu\text{g}/\text{kg}/\text{min}$
 - Titrate to effective dose
- Dose range is 2-20 $\mu\text{g}/\text{kg}/\text{min}$
- Adverse reactions
 - Doses $> 20 \mu\text{g}/\text{kg}/\text{min}$
 - Intrapulmonary shunting
 - Occasional arrhythmias

Inopressor Therapy

Noradrenaline

- Potent vasopressor
 - Strong α_1 activity
 - Both inotropic and chronotropic activities
 - β_1 activity
 - Variable β_2 activity
 - Chronotropic – usually blunted by vagal reflex
 - ↑ myocardial oxygen consumption
- Thought of primarily as a pressor
 - Advocated in septic shock
 - Used in combination with either dopamine or dobutamine
- More maldistribution than the other adrenergics

Inopressor Therapy Noradrenaline

- Initial dose
0.3-0.5 $\mu\text{g}/\text{kg}/\text{min}$
Titration to effective dose
- Dose range
0.1-3 $\mu\text{g} / \text{kg}/\text{min}$
- Difficult cases
4 to 5 $\mu\text{g}/\text{kg}/\text{min}$
- Adverse reactions
Arrhythmias
 - Rare without pre-existing myocardial damage
Hypoxic ischemic or asphyxial disease
Sepsis

Inopressor Therapy Adrenaline


- Primarily beta activity at low doses - inotropic
 - β1, β2 activity
 - ↑ cardiac output
 - ↓ peripheral resistance
- Inopressor activity as the dose increases
 - α1, α2 activity as well as β1, β2 activity
- Metabolic affects
 - Hyperglycemia
 - ↑ lactate production
 - Rapid and may be dramatic
 - Easily reversible

Inopressor Therapy Adrenaline


- For its inotropic effect
 - Start 0.3-0.5 $\mu\text{g}/\text{kg}/\text{min}$
 - Titrate to an effective dose
- Dose range
 - 0.1-2.0 $\mu\text{g}/\text{kg}/\text{min}$
 - Difficult cases – 3 to 4 $\mu\text{g}/\text{kg}/\text{min}$
- Adverse reaction
 - Metabolic derangements
 - Occasional arrhythmias
 - With pre-existing myocardial damage
 - Hypoxic ischemic asphyxial disease
 - Sepsis

Inopressor Combinations

- Dobutamine – Dopamine
- Dobutamine – Noradrenaline
- Adrenaline – Noradrenaline
- Dobutamine – Dopamine – Noradrenaline
- Dobutamine – Vasopressin***



Low-Dose Vasopressin Treatment for Septic Shock in Neonates



Vasopressin Release

- Increase plasma osmolarity
- Baroreflex response
 - Decrease blood volume
 - Decrease blood pressure
- Other stimuli
 - Adrenergic agents
 - Pain, Stress
 - SIRS – Cytokines, Prostaglandin
 - Hypoxia, Hypercapnia

Vasopressin Receptors

- Vascular V_1 receptors (V_{1a})
Causes vasoconstriction
- Renal V_2 receptors (antidiuretic action)
Aquaporin 2 channels
- Anterior pituitary V_3 receptors (V_{1b})
Stimulates the release of ACTH
Role in memory, emotion
- Oxytocin receptors
Mixed vasodilatation/constriction

Vasopressin

Blood Pressure

- Pressor action
 - Traditionally thought pharmacologic effect
 - More potent than Angiotensin II, noradrenaline
- Increases systemic vascular resistance
 - V₁ receptors in the medulla oblongata
 - Reset the cardiac baroreflex
 - Slows heart rate – arterial pressure unchanged
- Baroreceptor dysfunction
 - Sympathetic nerve impairment
 - Autonomic failure
 - Enhanced pressor activity of vasopressin

Vasopressin

Vasoconstrictor Activity

- Role in the regulation of arterial pressure
- Hypovolemic states
 - Water deprivation
 - Hemorrhage
 - Fluid loss
- Septic shock
 - Very sensitive to the pressor action
 - Vasopressin blood level very low
 - Cytokine levels should stimulate vasopressin release


Inappropriately Low Levels in Septic Shock

- Impaired baroreflex-mediated secretion
- Secondary to autonomic failure
- Depleted pituitary vasopressin stores

Excessive secretion in early stages of septic shock

Exhaustion of stores of vasopressin

Resuscitation of the Critical Foal Vasopressin



Dose used in foals
0.25-1.0 mU/kg/min

Infusion of Exogenous Vasopressin


- Increase in systolic pressure
 - Patients in septic shock
 - Not occur in normal subjects
- Vasoconstrictor action low dose vasopressin
 - Blood pressure maintained without catecholamines
 - Result in plasma concentrations near normal levels
- Septic shock
 - Vasopressin secretion is inappropriately low
 - Pressors sensitivity to vasopressin is enhanced
 - Autonomic failure

Urine flow rates

- Increase significantly
 - Improve renal perfusion
 - Constrict only the efferent arterial
 - Maintaining glomerular filtration rate
- Tubular effect (V_2)
 - Not present
 - Why?

Hypoperfusion in Septic Shock

Initially responsive
Becomes refractory




Septic Shock

Mechanism of Hypotension



- Active vasodilation
 - Initiators of SIRS
 - TNF, IL-1, other cytokines
 - Increase generation of local NO
- Abnormalities in vasoconstriction
 - Adrenergic down-regulation


Normal Vasoconstriction



**Voltage-gated
Ca Channels**

**Ca-gated
K channels**


Vasoconstriction vs. Vasodilatation




Vasodilatory Shock

Hyperpolarization

Vasodilatation



From: Landry DW and Oliver JA. NEJM 345(8): 588-595, 2001.



Sepsis

Hypotension

Lactic acidosis

CNS

Exhaustion of vasopressin


Relative vasopressin deficiency

↑ NO

K_{ATP} channels open

Downward spiral of hypoperfusion
Vasodilatory Shock

Catecholamine resistance



Exogenous Vasopressin



Physiologic Levels



Inhibits Nitric Oxide Production


Prevents Myocyte Hyperpolarization



Catecholamines
(endogenous or exogenous)
Effective




Stable Hemodynamic State



Low-dose Arginine Vasopressin Pressor Therapy Foals

- Dose
 - 0.25-0.5 mU/kg/min
- Constant infusion
- Response within minutes
 - Inotrope/Pressor Score 20 – 60
 - BP increase \sim 20 mmHg
 - Signs of perfusion improve
- Cost



Premature Friesian Foal

- 280 - 300 days gestation

Small- 25 kg

- Clinical Problems

Intrauterine acceleration of maturation

Neonatal Encephalopathy

Neonatal Nephropathy

Neonatal Gastroenteropathy

Incomplete ossification

SIRS



Premature Friesian Foal



- Admission

Poor perfusion – fully compensated shock

BP - 77/47 (57) 92

Respond well to fluid therapy +
dobutamine

BP - 105/67 (80) 90

- At 12 hrs

On dobutamine

BP – 86/62 (67) 104

Off dobutamine

BP – 67/44 (51) 99



Premature Friesian Foal

- At 48 hrs on Dobutamine (10 $\mu\text{g}/\text{kg}/\text{min}$)
BP – 50/28 (36) 88 and deteriorating perfusion
- Dobutamine (20 $\mu\text{g}/\text{kg}/\text{min}$)
→ BP 43/32 (38) 88
- Dobut + Dopamine (10 $\mu\text{g}/\text{kg}/\text{min}$)
→ 43/26 (32) 100
Inotrope/Pressor Score = 60 with no improvement
- Dobut + Dop + Vasopressin (0.25 mU/kg/min)
→ 69/41 (57) 100 and perfusion improved
- Cardiovascular stability until day 7
adrenaline , noradrenaline
Cardiovascular failure

Basic Principles of Cardiovascular Support

Insure Volume Tissue Perfusion Pressure



Hypotension

Other Therapeutic Interventions

- Low dose steroid therapy

Hypotensive secondary to adrenal insufficiency

- Premature neonates

Dexamethasone – 0.02 to 0.03 mg/kg

Cortisol – 1 mg/kg QID

Solu-cortef®

May result in a dramatic increase in BP

Adverse reaction

- Refractory hyperglycemia
- In human neonates, a poorer long-term outcome

Hypotension

Other Therapeutic Interventions

- Methylene blue

NO blocker

Refractory hypotension – septic shock

Dramatic resolution of hypotension

- Concurrent maldistribution of perfusion
- Resulting in negative outcomes

Recent publications in human critical care

- vasoplegic syndrome – cardiac surgery

- Naloxone therapy

Enhancement of adrenergic inotropic effects in sepsis

Correct maldistribution of perfusion

Anecdotal experience not encouraging









